Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Astrazeneca Plc (NY: AZN)
40.12 USD  -0.61 (-1.50%)
Official Closing Price  /  Updated: 4:40 PM EDT, Jul 19, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 3,709,600
Open 40.52
Bid (Size) 39.50 (1)
Ask (Size) 42.00 (3)
Prev. Close 40.73
Today's Range 40.06 - 40.59
52wk Range 35.30 - 43.30
Shares Outstanding 2,533,294,824
Dividend Yield 3.41%
Performance
YTD
+6.14%
+6.14%
1 Month
-3.74%
-3.74%
3 Month
+3.54%
+3.54%
6 Month
+9.77%
+9.77%
1 Year
+8.34%
+8.34%
Top News
More News
PRESS DIGEST- British Business - July 17
The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. Read More
category companyNews
from Reuters: Company News
FOCUS-As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff
For much of its 141-year history, Japan's Shionogi & Co Ltd has played safe when selling its drugs in the United States and other overseas markets - relying on bigger partners to promote its products... Read More
category companyNews
from Reuters: Company News
More News
Read More
PRESS DIGEST- British Business - July 16
category companyNews
from Reuters: Company News
UPDATE 2-GSK drug helps ovarian cancer patients live longer in late-stage study
category companyNews
from Reuters: Company News
AstraZeneca Trying To Close In On Key Technical Benchmark
from Investor's Business Daily
UPDATE 1-AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes
category companyNews
from Reuters: Company News
Foundation Medicine Expands Indication for FoundationOne®CDx as a Companion Diagnostic for LYNPARZA® (Olaparib)
from Business Wire News Releases
UPDATE 1-GSK's ovarian cancer treatment meets main goal in late-stage study
category companyNews
from Reuters: Company News
RPT-AstraZeneca's Farxiga fails to get FDA approval for Type-1 diabetes
category companyNews
from Reuters: Company News
IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer
from Business Wire News Releases
AstraZeneca's Farxiga fails to get FDA approval for Type-1 diabetes
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X